13337-66-1 Usage
General Description
7-Chloroquinoline-4-carboxylic acid is a chemical compound with the molecular formula C10H6ClNO2. It is a heterocyclic aromatic compound, containing a quinoline ring fused to a carboxylic acid group at the 4-position. 7-chloroquinoline-4-carboxylic acid is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and dyes. It has also been investigated for its potential use as an antimalarial agent. 7-Chloroquinoline-4-carboxylic acid is a valuable building block in organic synthesis due to its reactivity and versatility in forming various derivatives and functionalized compounds. Additionally, its unique structure makes it an important target for researchers exploring its biological and medicinal properties.
Check Digit Verification of cas no
The CAS Registry Mumber 13337-66-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,3,3,3 and 7 respectively; the second part has 2 digits, 6 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 13337-66:
(7*1)+(6*3)+(5*3)+(4*3)+(3*7)+(2*6)+(1*6)=91
91 % 10 = 1
So 13337-66-1 is a valid CAS Registry Number.
InChI:InChI=1/C10H6ClNO2/c11-6-1-2-7-8(10(13)14)3-4-12-9(7)5-6/h1-5H,(H,13,14)
13337-66-1Relevant articles and documents
-
Lutz et al.
, p. 1260,1263 (1947)
-
NOVEL FAP INHIBITORS
-
Paragraph 0365; 0422; 0443, (2014/12/09)
The present invention relates to novel inhibitors having high selectivity and specificity for FAP (fibroblast activation protein). Said inhibitors are useful as a human and/or veterinary medicine, in particular for the treatment and/or prevention of FAP-related disorders such as but not limited to proliferative disorders.
NOVEL FAP INHIBITORS
-
Page/Page column 58, (2013/07/31)
The present invention relates to novel inhibitors having high selectivity and specificity for FAP (fibroblast activation protein). Said inhibitors are useful as a human and/or veterinary medicine, in particular for the treatment and/or prevention of FAP-related disorders such as but not limited to proliferative disorders.
